33 results about "Tenascin C" patented technology

There is provided a panel of biomarkers of tumour metastasis comprising any two of carbonic anhydrase-9 (CAIX), vascular endothelial growth factor C (VEGF-C), ephrin A5 (EFNA5), eph receptor B2 (EPHB2), transforming growth factor beta 3 (TGF-β3), pyruvate dehydrogenase kinase isoenzyme-3 (PDK3), carbonic anhydrase-12 (CAXII), keratin 14 (KRT14), hypoxia inducible factor 1 alpha subunit (HIF-1α), or tenascin C (TNC). CAIX, VEGF-C, EFNA5, EPHB2, TGF-β3 or PDK3 may be indicators of moderate metastatic potential, while CAXII, KRT14, HIF-1α, or TNC may be indicators of high metastatic potential. There is also provided a method of determining risk of tumour metastasis using the aforementioned biomarkers is also provided. The biomarkers may be used in diagnosis, prognosis, treatment selection, or to test putative therapeutics. The biomarkers may be used to assess malignancies or cancers having hypoxic regions, such as breast cancer.

The disclosure includes assays and methods for screening for risk of Down syndrome and / or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and / or CPA1 polypeptide and / or an increased level of APP and / or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.

The invention relates to Tenascin-C and peptides that bind thereto. According to the invention, Tenascin-C or peptides and antibodies that bind thereto can be used to treat or prevent vascular diseases, either alone or in combination with therapeutic agents or cells that have cardioplastic potential.

The invention relates to a diagnostic marker for the colorectal cancer and a detection product for the colorectal cancer and an application thereof. The colorectal cancer diagnostic marker comprises aplurality of kinds of secreted protein including one or more of S100A9 protein, tenascin-c protein and CEA protein. The diagnostic marker has characteristics of high sensitivity and strong specificity. The area under the roc curve of the diagnostic model is 0.902. The confidence level of the diagnosis result is much higher than that of the diagnosis result using a single protein marker. The diagnostic marker has the important significance in colorectal cancer diagnosis and treatment. Besides, the detection product of the colorectal cancer includes the colorectal cancer diagnostic marker. In addition, the invention also puts forward application of the colorectal cancer diagnostic marker in preparation of a product for the auxiliary diagnosis of the colorectal cancer.

The invention relates to novel bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to tenascin C (TnC), and to methods of producing these molecules and to methods of using the same.

The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (DETA); verifying DETA monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the DETA monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating. A cell nutrient medium composition includes Neurobasal, an antibiotic-antimycotic composition, cholesterol, human TNF-alpha, PDGF BB, vasoactive intestinal peptides, insulin-like growth factor 1, NAP, r-Apolipoprotein E2, purified mouse Laminin, beta amyloid, human tenascin-C protein, rr-Sonic hedgehog Shh N-terminal, and rr-Agrin C terminal.

The invention relates to a method of determining the inflammatory disorder status of a subject comprising detecting the presence or absence, or the level, of (i) citrullinated tenascin-C and / or one or more fragments of citrullinated tenascin-C; and / or (ii) autoantibodies with specificity for citrullinated tenascin-C and / or one or more fragments of citrullinated tenascin-C, in a sample from said subject.

The invention relates to an isonucleoside or isonucleoside and 2'-deoxyinosine modified tenascin-C aptamer GBI-10 as well as a preparation method and an application thereof and belongs to the field of biological medicines. Nucleotides in different positions of a tenascin-C aptamer GBI-10 are substituted with isonucleoside or isonucleoside and 2'-deoxyinosine, local spatial conformation of the aptamer is changed, the space structure is optimized, and accordingly, the isonucleoside or isonucleoside and 2'-deoxyinosine modified tenascin-C aptamer GBI-10 is obtained. An experiment proves that the isonucleoside or isonucleoside and 2'-deoxyinosine modified tenascin-C aptamer GBI-10 has higher affinity and a high-specificity target identification function on target protein as well as higher biological activity. Accordingly, efficient, high-selectivity and low-toxic anti-tumor medicines can be prepared from the isonucleoside or isonucleoside and 2'-deoxyinosine modified tenascin-C aptamer GBI-10 potentially, and the isonucleoside or isonucleoside and 2'-deoxyinosine modified tenascin-C aptamer GBI-10 can also be applied to reagents for early detection of tumor.

The present invention relates to a small molecule polypeptide TP-7 having a function of inhibiting a renal fibrosis-promoting function of extracellular matrix tenascin C (TNC) and particularly to a use of the small molecule polypeptide TP-7 in preparation of medicines for treating chronic kidney diseases (CKD). An amino acid sequence of the polypeptide TP-7 is shown in SEQ ID NO.1. In multiple mouse kidney fibrosis models, the TP-7 has a significant effect, can obviously restore renal functions, inhibits progress of renal fibrosis, is also free of obvious toxic and side effects, and thus can be prepared into pharmaceutical preparations for treating the chronic kidney diseases.

The present disclosure provides methods for isolating tumor-derived microparticles from a subject for analysis, specifically by isolating Tenascin-C positive microparticles from a sample from the subject to obtain tumor-derived microparticles. Methods for determining the expression status of biomarkers in the tumor-derived microparticles and methods for determining additional characteristics of the tumor-derived microparticles are also provided.

The invention discloses a group of colon cancer metastasis related tumor stroma markers. The group of marks exist in a tumor stroma, and marker expression abnormality is also more obvious along with the development of canceration, wherein one marker Tenascin-C belongs to a novel extracellular matrix marker, generates abnormal expression in the early stage of tumor canceration, and also generates abnormal expression in a metastasis position, wherein the marker for the self secretion of a tumor is relevant to the metastasis capability. The group of markers can be used for preparing medicines and a kit for colon cancer metastasis screening and auxiliary diagnosis.

The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFR1), CRP, VCAM-1, thrombopoietin, α2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-α), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.

The invention belongs to the technical field of biomedicines, and relates to an application of Tenascin-C in the preparation of kidney injury diagnosis and treatment preparations. The Tenascin-C is used as a kidney injury or kidney fibration biomarker, and especially used as a biomarker in kidney injury or kidney fibration blood and urea. The invention provides an application of the Tenascin-C in the preparation of kits for detecting, diagnosing and treating kidney injury or kidney fibration. The biomarker indexes of the blood and the urea are monitored to reflect the severe degree of the kidney injury and predicate the kidney recovery opportunity, and intervention measures for promoting restoration of acute kidney injury and mitigation of the severe degree of the kidney injury are provided; and the biomarkers of the blood and the urea are monitored to reflect the severe degree of the kidney fibration, and intervention measures for facilitating early stage diagnosis of chronic kidney fibration and monitoring of the kidney fibration progress are provided.

The present invention provides a method of determining the rheumatoid arthritis status of a subject, or the progression of rheumatoid arthritis, or the appropriate treatment for a subject with rheumatoid arthritis, comprising the steps of (a) determining the level of tenascin-C in a sample from said subject; and (b) comparing the level of tenascin-C determined in step (a) with one or more reference values. Preferably the rheumatoid arthritis referred to is erosive rheumatoid arthritis. The invention, when being disclosed, is accompanied with Figure 5.

The invention relates to a composition for the treatment of various cancers. The composition is a vaccine containing sequences of EDB, EDA, annexin A1, endosialin, C domain of tenascin C or magic roundabout (MR) or fragments thereof as single or in a combination coupled to one or several heterologous foreign carrier molecules. The vaccine will produce antibodies that are directed against self proteins which are preferentially expressed in and around tumor vessels. The vaccine is preferably administrated together with an adjuvant.

The invention provides a remedy for chronic inflammation and an anti-TNIIIA2 antibody to be used therein. The remedy includes an antibody recognizing TNIIIA2, that is a peptide derived from a partial sequence A2 of a human tenascin-C fibronectin III-like repetitive sequence and having the amino acid sequence RSTDLPGLKAATHYTITIRGVC (SEQ ID NO: 1).

The invention belongs to the field of molecular biological marker diagnosis and prognosis evaluation and relates to an application of a urea Tenascin-C: creatinine in preparing preparation for diagnosing and prognosis evaluating idiopathic IgA nephropathy. The urea Tenascin-C: creatinine (uTNC / Cr) as a marker can be used for diagnosing the severity of illness of the idiopathic IgA nephropathy andprognosis evaluation. By detecting the level of the urea Tenascin-C: creatinine, a result shows that the uTNC / Cr level of a patent with idiopathic IgA nephropathy is higher than that of a normal person, and the urea TNC is ejected along with urea after lesion expression of segment glomerular sclerosis, crescent in kidney tissues and the like. Meanwhile, the uTNC / Cr level can reflect the expressionquantity of TNC of glomerulus, reflect the severity of lesion of IgA nephropathy and can assist prognosis evaluation of the IgA nephropathy indirectly. The invention provides a preparation which is time-saving, high in sensitivity and accuracy, low in cost and efficient in diagnosing and prognosis evaluating idiopathic IgA nephropathy compared with prior art and a kit for the application.

The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (DETA); verifying DETA monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the DETA monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating. A cell nutrient medium composition includes Neurobasal, an antibiotic-antimycotic composition, cholesterol, human TNF-alpha, PDGF BB, vasoactive intestinal peptides, insulin-like growth factor 1, NAP, r-Apolipoprotein E2, purified mouse Laminin, beta amyloid, human tenascin-C protein, rr-Sonic hedgehog Shh N-terminal, and rr-Agrin C terminal.

The invention relates to a tenascin C nucleic acid aptamer GBI-10 modified with isonucleosides or isonucleosides combined with 2'-deoxyinosine, and a preparation method and applications thereof, belonging to the field of biomedicine. In the present invention, isonucleosides or isonucleosides combined with 2'-deoxyinosine are used to replace nucleotides in different positions of tenascin C nucleic acid aptamers GBI-10, so as to change the local spatial conformation of the nucleic acid aptamers, and optimize the Its spatial structure is obtained, thereby obtaining an isonucleoside or isonucleoside combined with 2'-deoxyinosine modified tenascin C nucleic acid aptamer GBI-10. Experiments show that the tenascin C nucleic acid aptamer GBI-10 modified by this method has stronger affinity with the target protein, more specific target recognition, and higher biological activity. Therefore, it is hoped that the isonucleosides or isonucleosides combined with 2'-deoxyinosine-modified tenascin C nucleic acid aptamer GBI-10 can be prepared into anti-tumor drugs with high efficiency, high selectivity, and low toxic and side effects. It is used in tumor early detection reagents.

The invention provides antibodies against the A2 domain of tenascin-C and methods of using the same.

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one antigen binding moiety capable of specific binding to Tenascin-C (Tn C) and (b)a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecules are characterized in that the first polypeptide comprises two ectodomains ofa TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof. The invention further relates to methods of producing these molecules and to methods of using the same.

Provided is a novel ligand for integrin α9β1 consisting of a peptide having the following amino acid sequence:(A) EDDMMEVPY (SEQ ID NO: 1) or(B) an amino acid sequence the same as the amino acid sequence represented by SEQ ID NO: 1 except for having deletion, substitution or addition of 1 to 3 amino acids. The novel ligand for integrin α9β1 has a higher binding affinity than those of tenascin-C and osteodontin, which are known ligands for integrin α9β1.

There is provided agents for modulation of a chronic inflammatory response wherein the agent modulates the biological activity of citrullinated tenascin-C. There is also provided methods of identifying agents modulating citrullinated tenascin-C and chronic inflammation. There are also provided therapeutic uses of such agents.

Specific binding members against extracellular matrix protein tenascin-C, especially scFv antibody molecules against domain A1, domain C and domain D of tenascin-C. Anti-tenascin-C specific binding members conjugated with labels, cytotoxic molecules or cytokines. Use of anti-tenascin-C specific binding members in diagnosis and treatment, especially of cancer.